Table 5.
Surgical management in women with node-positive breast cancer undergoing neoadjuvant endocrine therapy
| Surgery | All patients | Post-neoadjuvant axillary status | ||
|---|---|---|---|---|
| pN0 | pN+ | p | ||
| n | 4580 | 663 | 3917 | |
| Primary (N, %) | ||||
| Lumpectomy | 1152 (25.2) | 215 (32.4) | 937 (23.9) | < 0.001 |
| Mastectomy | 3406 (74.4) | 446 (67.3) | 2960 (75.6) | |
| Other/unknown | 22 (0.5) | 2 (0.3) | 20 (0.5) | |
| Axilla (*2012 and later) (N, %) | ||||
| None | 80 (2.4) | 32 (6.2) | 48 (1.7) | < 0.001 |
| Biopsy | 12 (0.4) | 3 (0.6) | 9 (0.3) | |
| SLNB | 483 (14.2) | 186 (36.1) | 297 (10.3) | |
| ALND | 2152 (63.4) | 224 (43.5) | 1928 (67.0) | |
| SLN + ALND | 659 (19.4) | 70 (13.6) | 589 (20.5) | |
| Other/unknown | 6 (0.2) | 0 (0.0) | 6 (0.2) | |
pN0 pathologically node-negative, pN+ pathologically node-positive, N node, SLNB sentinel lymph node biopsy, ALND axillary node dissection